[1] ZHAO P, LI J, YU L, et al.Clinical Manifestations and Risk Factors of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1 Inhibitors: a Case-Control Study[J]. Front Immunol, 2025, 16: 1581057. [2] WANG MX, LIU AX, SUN QM, et al.Sintilimab for the Treatment of Lung Adenocarcinoma-Induced Immune-Related Hypophysitis: a Case Report[J]. Front Immunol, 2025, 16: 1534179. [3] HUANG L.A Case of Sintilimab-Induced Hypophysitis in Advanced Esophageal Carcinoma[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2022, 31(11): 781-783. [4] LIU Z, MA Q, MA S, et al. Isolated Adrenocorticotropic Hormone Deficiency Associated with Sintilimab in the Treatment of Lung Adenocarcinoma: a Case Report and Literature Review[J/OL]. Endocr Res,[2025-04-21](2025-05-01). https://pubmed.ncbi.nlm.nih.gov/40257860/. [5] REN GL, WU XS, SANG QJ, et al.Two Cases of Sintilimab-Induced Immune-Related Thyroid Dysfunction: Case Reports and Literature Analysis[J]. Pharmaceutical Journal of Chinese People's Liberation Army(解放军药学学报), 2025, 38(1): 104-107. [6] VARDARLI I, TAN S, BRANDENBURG T, et al.Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Monoor Combination Therapy in Solid Tumors: a Meta-Analysis of Randomized Controlled Trials[J]. J Clin Endocrinol Metab, 2024, 109(4): 1132-1144. [7] ZHOU Y, DU X, HUANG Y, et al.Risk Factors for Hypothyroidism in Non-Small Cell Lung Cancer Patients Treated with Sintilimab[J]. Chinese Journal of Clinicians(中国临床医生杂志), 2024, 52(2): 141-144. [8] GAO Y, YE T, WU L G, et al.The Association between Baseline TPOAb and/or TgAb Positivity and Thyroid Immune-Related Adverse Events in Patients with Malignancies Following Treatment with Immune Checkpoint Inhibitors[J]. National Medical Journal of China(中华医学杂志), 2024, 104(12): 963-969. [9] WANG L, TANG JL, LI CH, et al.One Case of Acute Severe Liver Injury Caused by High-Dose Dexamethasone Sodium Phosphate Injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2025, 22(5): 589-591. [10] YUWEN LX, SHI HH, WANG RL, et al.Clinical Pharmacists Participated in Thepharmaceutical Practice of a Patient with Immune-Related Hypothyroidism Caused by Sintilizumab[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2023, 32(9): 701-703. [11] AVIV-SHIMONI S, URI I, MILLOH-RAZ H, et al.Isolated Autoi-mmune Adrenocorticotropic Hormone Deficiency: a Positive Predictor of Survival Among Cancer Patients Treated with Checkpoint Inhibitors[J]. Autoimmun Rev, 2023, 22(9): 103387. [12] WANG F, SHI X, YU X, et al.Immune Checkpoint Inhibitor-Induced Isolated Adrenocorticotropic Hormone Deficiency: a Systematic Review[J]. Front Endocrinol (Lausanne), 2024, 15: 1326684. [13] KARAVITI D, KANI ER, KARAVITI E, et al.Thyroid Disorders Induced by Immune Checkpoint Inhibitors[J]. Endocrine, 2024, 85(1): 67-79. [14] MOSAFERI T, TSAI K, SOVICH S, et al.Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism is Distinct from Hashimoto's Thyroiditis[J]. Thyroid, 2022, 32(5): 496-504. [15] QIN SK, WANG BC, GUO J, et al.Chinese Society of Clinical Oncology(CSCO) Guidelines for the Management of Immune Checkpoint Inhibitor-Associated Toxicity(中国临床肿瘤学会免疫检查点抑制剂相关毒性管理指南)[M]. Beijing: People's Medical Publishing House, 2023: 1-185. |